Children in VA Given Adult Version of Pfizer Vax

Parents Told to Wait Three Weeks, Then Vax Again

Well, that didn’t take long.

A pharmacy in Loudoun County, VA has admitted to giving 112 children between the ages of 5 and 11 the adult version of the Pfizer Covid-19 vaccination, which contains a different formula than the child version and is three times stronger.

Ted Pharmacy is now under investigation and has been removed from the Covid-19 vaccination program after admitting to public health authorities that, rather than administering the child version of the Covid-19 vaccine to children in this age group, it simply cut the adult vaccine to attempt to mimic the child dose.

Parents are being told to monitor their children for side effects. Beyond that, the county health department has suggested that parents either wait three weeks, and start the two-dose regimen over, or proceed with the second dose of the child vax according to schedule.

Nowhere in the conversation is there any discussion of having the children’s antibodies levels tested before determining whether to vaccinate them any further. That would involve actual science. And this vaccination program clearly has nothing to do with science.

If it did, Pfizer would have tested all the children in the treatment arm of its clinical trial for antibodies after their first dose, to determine whether one dose might be sufficient. It tested none of them. Instead, the company merely assumed from the start of the trial that two doses would be needed.

Then again, had one dose been sufficient for children, that would have cut Pfizer’s sales of its child vaccine in half. It also would have blunted the “fully vaccinated” talking point that has become such a central part of this strange ritual.   To most people, “fully vaccinated” now means two doses (of whatever).

Had the Covid-19 vaccination program been based on actual science, Pfizer also would have acknowledged the superiority of natural immunity and admitted its vaccine likely offers only risks, no benefits, to children who have naturally acquired antibodies to SARS-CoV-2.

Then again, had Pfizer acknowledged the superior benefits of natural immunity, the pool of available child customers would have been reduced, right from the start, by at least half.